Sozen S - Search Results

1

Resection of residual masses alone: an alternative in surgical therapy of metastatic testicular germ cell tumors after chemotherapy.

Ozen H, Ekici S, Sozen S, Ergen A, Tekgül S, Kendi S. Ozen H, et al. Among authors: sozen s. Urology. 2001 Feb;57(2):323-7. doi: 10.1016/s0090-4295(00)00909-2. Urology. 2001. PMID: 11182346

2

Nuclear p53 overexpression in bladder, prostate, and renal carcinomas.

Sinik Z, Alkibay T, Ataoglu O, Biri H, Sözen S, Deniz N, Karaoglan U, Bozkirli I. Sinik Z, et al. Among authors: sozen s. Int J Urol. 1997 Nov;4(6):546-51. doi: 10.1111/j.1442-2042.1997.tb00306.x. Int J Urol. 1997. PMID: 9477181 Free article.

3

Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes.

Stamey TA, Donaldson AN, Yemoto CE, McNeal JE, Sözen S, Gill H. Stamey TA, et al. Among authors: sozen s. J Urol. 1998 Dec;160(6 Pt 2):2412-7. doi: 10.1097/00005392-199812020-00009. J Urol. 1998. PMID: 9817394 Free article.

4

Glutathione S-transferase M1 gene polymorphism in bladder cancer patients. a marker for invasive bladder cancer?

Aktas D, Ozen H, Atsu N, Tekin A, Sozen S, Tuncbilek E. Aktas D, et al. Among authors: sozen s. Cancer Genet Cytogenet. 2001 Feb;125(1):1-4. doi: 10.1016/s0165-4608(00)00307-1. Cancer Genet Cytogenet. 2001. PMID: 11297759

5

Combined use of prostate-specific antigen derivatives decreases the number of unnecessary biopsies to detect prostate cancer.

Ozen H, Aygün C, Ergen A, Sözen S, Aki FT, Uygur MC. Ozen H, et al. Among authors: sozen s. Am J Clin Oncol. 2001 Dec;24(6):610-3. doi: 10.1097/00000421-200112000-00017. Am J Clin Oncol. 2001. PMID: 11801765

6

Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory).

Sözen S, Akbal C, Sökmensüer C, Ekici S, Ozen H. Sözen S, et al. Urol Int. 2002;69(3):200-6. doi: 10.1159/000063941. Urol Int. 2002. PMID: 12372888

7

Urinary markers for urothelial cancer.

Sözen S, Eskicorabci S, Ozen H. Sözen S, et al. BJU Int. 2003 Oct;92(6):531-3. doi: 10.1046/j.1464-410x.2003.04427.x. BJU Int. 2003. PMID: 14511027 Review. No abstract available.

8

CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population.

Aktas D, Hascicek M, Sozen S, Ozen H, Tuncbilek E. Aktas D, et al. Among authors: sozen s. Cancer Genet Cytogenet. 2004 Oct 1;154(1):81-5. doi: 10.1016/j.cancergencyto.2004.01.023. Cancer Genet Cytogenet. 2004. PMID: 15381379

9

Validation of 2001 Partin tables in Turkey: a multicenter study.

Eskicorapci SY, Karabulut E, Türkeri L, Baltaci S, Cal C, Toktas G, Akpinar H, Ozer G, Sozen S, Tokuc R, Lekili M, Soylu A, Albayrak S, Sahin H, Alpar R, Ozen H. Eskicorapci SY, et al. Among authors: sozen s. Eur Urol. 2005 Feb;47(2):185-9. doi: 10.1016/j.eururo.2004.08.002. Eur Urol. 2005. PMID: 15661412

10

Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.

Sözen S, Eskicorapci S, Küpeli B, Irkilata L, Altinel M, Ozer G, Uygur C, Alkibay T, Ozen H. Sözen S, et al. Eur Urol. 2005 Mar;47(3):302-7. doi: 10.1016/j.eururo.2004.10.009. Epub 2004 Dec 1. Eur Urol. 2005. PMID: 15716190 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

178 results

Search Page

Filters